Haqq Christopher 4

What Happened

• Christopher Haqq, Executive Vice President, Head of R&D and Chief Medical Officer of Elicio Therapeutics (ELTX), was granted equity awards on 2026-02-02: 25,400 restricted stock units (RSUs) and 50,900 option-based awards (reported as a derivative). Both awards were granted at $0.00 (no cash paid).

Key Details

• Transaction date: 2026-02-02. Report filed 2026-02-03 (period of report 2026-02-02).
• Grants: 25,400 RSUs (each RSU equals the right to one share) and 50,900 option-based derivative awards. Report shows acquisition code "A" (award/grant).
• Price/Value: $0.00 reported for both grants (typical for equity compensation grants).
• Vesting (per footnotes): RSUs vest 25% on Feb 2, 2027, then in annual installments over the next three years; the options vest 25% on Feb 2, 2027, with the remainder vesting monthly over the following three years.
• Shares owned following the transaction: not specified in the filing.
• Filing timeliness: filing date provided; no late filing flag noted.

Context

• These awards are compensation grants that will convert to stock or become exercisable over multi-year vesting schedules if Haqq remains in service; they do not represent an immediate open-market purchase or sale.
• The derivative entry reflects stock options (vesting/exercisable schedule) rather than an immediate exercise or sale.